Drug, bio-affecting and body treating compositions inventions 12/06

20060292072 - Agents for neutron capture therapy: Compounds, pharmaceutical formulations and methods for use in neutron capture therapy are provided, useful for treating diseases characterized by neoplastic tissue and arteriosclerosis.... Agent: Wilson Sonsini Goodrich & Rosati

20060292073 - Stereoselective synthesis of amino acid analogs for tumor imaging: The radiolabeled non-natural amino acid 1-amino-3-cyclobutane-1-carboxylic acid (ACBC) and its analogs are candidate tumor imaging agents useful for positron emission tomography and single photon emission computed tomography due to their selective affinity for tumor cells. The present invention provides methods for stereo-selective synthesis of syn-ACBC analogs. The disclosed synthetic strategy... Agent: Greenlee Winner And Sullivan P C

20060292074 - Tomoregulin antibodies and uses thereof: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against a Tomoregulin (TR) polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.... Agent: Berlex Biosciences Patent Department

20060292075 - Labelled glutamine and lysine analogues: Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for... Agent: Ge Healthcare, Inc.

20060292076 - Antimicrobial mediated ozone generation: The invention provides methods of detecting antibodies and neutrophils that can generate reactive oxygen species.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20060292079 - Conjugates of hydroxypyridinone derivative metal complexes with biomolecules and their use for mri diagnosis: The invention relates to conjugates of hydroxypyridinone derivative metal complexes and to their preparation. The conjugates are suitable as contrast agents in NMR diagnosis. A high relaxivity is achieved and the NMRD maximum is raised through a specific design of the ligands.... Agent: Fish & Richardson P.C.

20060292077 - Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same: In accordance with the present invention, a high intensity radiopaque contrast agent is disclosed. The agent may be coated on or incorporated within bulk material which may then be subsequently utilized to fabricate a radiopaque medical device. Primary effects through chemistry include higher radiopaque concentrations per unit weight of the... Agent: Philip S. Johnson Johnson & Johnson

20060292078 - Optical imaging of colorectal cancer: The invention provides contrast agents for optical imaging of colorectal cancer (CRC) in patients. The contrast agents may be used in diagnosis of CRC, for follow up of progress in disease development, and for follow up of treatment of CRC. Further, the invention provides methods for optical imaging of CRC... Agent: Ge Healthcare, Inc.

20060292080 - Vitamin formulation: A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the... Agent: Townsend And Townsend And Crew, LLP

20060292082 - Dry powder inhaler: A dry powder inhaler for delivering a dose of medicament for inhalation by a user, including a drug entrainment device and a valve actuable by a user to cause pressurised gas to flow through a dose of medicament disposed in the drug entrainment device to entrain said dose in the... Agent: Davidson, Davidson & Kappel, LLC

20060292083 - Inhalation compositions with high drug ratios: The invention provides a dry powder inhalation composition comprising, at least 0.25% by weight of the composition of an active ingredient with a particle size of less than 10 microns in diameter and a pharmaceutically acceptable particulate carrier with a particle size of less than 250 microns in diameter. Also... Agent: Ivax Corporation

20060292085 - Medicaments: There is described a bimodal pharmaceutical composition comprising effective amounts of a first active ingredient which substantially comprises a coarse fraction and a second active ingredient which substantially comprise a fine fraction characterized in that the coarse fraction possesses a greater mass median aerodynamic diameter than the fine fraction. There... Agent: Nixon Peabody LLP - Patent Group

20060292081 - Methods for preparing pharmaceutical compositions: The present invention relates to improvements in dry powder formulations comprising a pharmaceutically active agent for administration by inhalation, and in particular to methods of preparing dry powder compositions with improved properties. In particular, spray drying processes are adapted and adjusted to obtain active particles with higher fine particle fractions... Agent: Davidson, Davidson & Kappel, LLC

20060292084 - Process for cleaning hard gelatine capsules: A process which can be used in the laboratory or on an industrial scale for cleaning the inner wall of hard gelatine capsules, in which the sealed capsules are cleaned with a powder formulation.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20060292086 - Antimicrobial composition: An antimicrobial composition is provided. The antimicrobial composition has broad antimicrobial efficacy in a format convenient for no-rinse application to the skin. The composition dries quickly, leaves the skin smooth, comfortable and adequately moisturized. A method of making the antimicrobial composition, a method of sanitizing skin using the antimicrobial composition,... Agent: Foley And Lardner LLP Suite 500

20060292088 - Compositions and methods for altering the color of teeth: Compositions for altering the color of teeth, including tooth-coating compositions comprising a colorant and an acrylate polymer. Colorants among those useful herein include whiteness-imparting particulate materials, such as hydroxyapatite.... Agent: Colgate-palmolive Company

20060292087 - Dentrifrice and method of making the same: A dentifrice includes a carrier material and a plurality of particles in the carrier material. The plurality of particles includes multiple regions of different colored materials and an outer region which at least partially encapsulates the multiple regions of different colored materials. The multiple regions of different colored materials dissolve... Agent: Michael Winfield Goltry

20060292089 - Periodontal regeneration composition and method of using same: A periodontal structure regeneration composition for treatment of periodontal disease is a mixture of particles of a bone growth material and free collagen. All particles are sized to be less than 1 mm in diameter. The periodontal regeneration composition is injected into the periodontal pocket through an 18 gauge needle.... Agent: Buchanan Ingersoll & Rooney PC

20060292090 - Oral care compositions, devices, and methods of using the same: Oral care compositions, devices and methods are disclosed that employ an amorphous calcium phosphate or a precursor or derivative thereof, and a tooth whitening agent.... Agent: Fish & Richardson P.C.

20060292092 - Oral care compositions, devices, and methods of using the same: Oral care compositions, devices and methods are disclosed that employ an amorphous calcium phosphate or a precursor or derivative thereof, and a tooth whitening agent.... Agent: Philip S. Johnson Johnson & Johnson

20060292091 - Tooth whitening compositions: (a) 10% to 75% of a complex which is (i) a mixture of 78 to 90% of water soluble polyvinylpyrrolidone (PVP) having K-values of K-12 to K-120 and (ii) 10 to 22% of H2O2; releasing 1 to 20% of active H2O2 from said complex onto a tooth surface; (b) 0... Agent: William J. Davis, Esq. International Specialty Products

20060292093 - Chromen-4-one derivatives: The invention relates to compounds that are selected from the compounds of formulas (Ia)-(Ic) and to their production and use in cosmetic and dermatological products.... Agent: Millen, White, Zelano & Branigan, P.C.

20060292094 - Composition and method of protection against uv irradiation: The present invention relates to a composition for use in a nutritional product, dietary supplement, or pharmaceutical compound wherein such composition is used to protect the skin against the effects of ultraviolet (UV) irradiation from the sun or other sources, including but not limited to sunburn, skin redness, swelling, immune... Agent: Amin Law, LLC

20060292095 - Gelled oil particles comprising at least one hydrophobic sunscreen: The present invention relates to calibrated oily particles comprising at least one hydrophobic sunscreen and comprising at least one oily phase structured with at least one gelling polymer, characterized in that it has a mean size of less than or equal to 20 μm, in that the said structured oily... Agent: Oliff & Berridge, PLC

20060292096 - Cosmetic compositions having enhanced wear properties: A cosmetic composition and process which provides enhanced wear and transfer resistance containing: (a) at least one polypropylsilsesquioxane film forming resin; (b) at least one solvent; and (c) optionally, at least one colorant.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20060292097 - Fragrance compositions comprising benzo[4,5]thieno{3,2-b]pyran-2-one: The present case discloses compositions of benzo[4,5]thieno[3,2-b]pyran-2-one which are employed as aroma chemicals.... Agent: Miles & Stockbridge PC

20060292098 - Consumer noticeable improvement in wetness protection: Antiperspirant compositions comprising: (a) from about 0.1% to about 30% by weight of the composition, of a high-efficacy antiperspirant active; (b) from about 0.05% to about 15% by weight of the composition, of a malodor reducing agent; (c) from about 0.1% to about 35% by weight of the composition, of... Agent: The Procter & Gamble Company Intellectual Property Division

20060292099 - Treatment of eye disorders with sirtuin modulators: Sirtuin modulators, particularly sirtuin activators, are useful in treating vision impairment. In general, the sirtuin modulators inhibit the progression of vision impairment resulting from various eye disorders. The invention also includes pharmaceutically acceptable formulations of sirtuin modulators, particular ophthalmically acceptable formulations.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20060292100 - Aqueous phospholipid-containing carrier systems for water-insoluble materials: The present invention is drawn to a carrier composition containing: (a) at least one phospholipid; (b) at least one nonionic surfactant; (c) at least one anionic silicone; and (d) at least one water-insoluble material, and wherein the composition, when combined with an aqueous phase, forms an aqueous delivery system which... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20060292101 - In-eye method of cleaning and/or disinfecting silicone hydrogel contact lenses: A method of treating a contact lens, and in some instances, a silicone hydrogel contact lens, in the eye of a wearer comprising i) applying to said contact lens and/or eye an ophthalmically compatible contact lens cleaning and/or hydrating and/or disinfecting solution; and ii) rubbing the eyelid associated with said... Agent: Bausch & Lomb Incorporated

20060292102 - Thixotropic personal lubricant: A thixotropic personal lubricant includes a high molecular weight, thixotropic, gel-forming, naturally occurring polysaccharide extracted from algae and comprised of repeating sulfated and non-sulfated galactose and 3,6 anhydrogalactose (3,6-AG) units, and includes water.... Agent: Tod R Nissle

20060292103 - Composition for skin use: A composition for skin use is disclosed. The composition for skin use comprises a high concentration of protein fiber dispersed in an emulsifier system that is consisted of at least one non-silicone surfactant. The emulsifier system has no silicone-containing component, so as to improve the disadvantages of the prior emulsifier... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20060292104 - Transparent or translucent conditioning composition packed into transparent and/or translucent container: Disclosed are hair or skin conditioning compositions wherein the composition is a rinse-off conditioning composition having a transparent or translucent appearance and comprising from about 0.1% to about 10% of a polymer and an aqueous carrier, wherein the composition is packed in a container having a transparent and/or translucent appearance,... Agent: The Procter & Gamble Company Intellectual Property Division

20060292105 - Topical preservative compositions: The use of one or more compositions of one or more preserving agents at a relatively high osmolality to disinfect contact lenses and preserve topical agents and ophthalmic lens compositions is described. Ophthalmic lens solutions containing one or more compositions of one or more preserving agents at a relatively high... Agent: Bausch & Lomb Incorporated

20060292106 - Shaving preparation: The present invention is directed to a composition and process for shaving a surface, such as human skin having hair projecting therefrom. The process involves the steps of: (a) providing a surface to be shaved; (b) providing a composition containing: (i) at least one non-aqueous polar organic compound having at... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20060292107 - Solid shaving composition and packaging system: A method of packaging and distributing substantially dehydrated shaving strips, wherein a solid strip of substantially dehydrated shaving lotion is provided. The shaving strips are cut or pressed into discreet units. Alternatively, the dehydrated shaving composition can be deposed onto a water soluble carrier strip. A plurality of shaving strips... Agent: Dougherty Clements

20060292109 - Enzyme inhibiting sprayable compositions: A skin barrier composition including a barrier component and an enzyme inhibiting component that is sprayable for use in ostomy and wound care, infant diapers, and fecal incontinence applications. The barrier component is based on petrolatum or other acceptable carriers, and the enzyme inhibitor component is derived from tubers, such... Agent: Bristol-myers Squibb Company

20060292108 - Topical skin mask for oily and acneic skin: A very efficient topical skin mask to reduce sebum, redness and inflammation of oily and acneic skin. The composition is produced by blending specific quantities of Zinc oxide, Kaolin, Lupini powder, Ascorbic acid and Sulfur, with Glycerin, Rose water and Distilled Water at room temperature and mixing with a high... Agent: Hanna Ibrahim 1st Floor

20060292110 - Coffee aroma vehicle air freshener: A car freshener comprising of a pre-formed material constructed to absorb a scent and a coffee flavored scent affixed to the pre-formed material.... Agent: NationalIPRights Center, LLC Scott J. Fields, Esq.

20060292111 - Composition and its physical requirements for eliminating odors in air: An air treating composition for eliminating odors from air in combination with specific spray valve and actuator requirements and spray performance parameters providing maximum dispersion of the active component in the composition into the air is disclosed. The particles of the composition are small so that the active component is... Agent: S.c. Johnson & Son, Inc.

20060292112 - Dendrimer-photosensitizer complexes for medical applications: A method for enhanced Photodynamic Therapy (PDT) treatments by applying dendrimer-photosensitizer complexes to bring multiple photosensitizer moieties to a treatment site is provided. The most benefit is derived for treatments using systemic introduction of the photosensitizer formulation. Photosensitizers are covalently coupled to the peripheral bonding places of dendrimers, using labile... Agent: Bolesh J. Skutnik Phd, Jd

20060292114 - Neurturin receptor: NTNRα, NTNRα extracellular domain (ECD), NTNRα variants, chimeric NTNRα (e.g., NTNRα immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNRα-ligands, for example NTN, by providing NTNRα to... Agent: Heller Ehrman LLP

20060292113 - Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer: The present invention provides prophylactic and therapeutic methods of treating the ductal epithelium of an exocrine gland, in particular a mammary gland, for disease, in particular cancer. The methods comprise contacting the ductal epithelium of the exocrine gland with an epithelium destroying agent, preferably by ductal cannulation, so as to... Agent: Barnes & Thornburg LLP

20060292116 - Interleukin-2 mutants with reduced toxicity: Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a... Agent: Foley & Lardner LLP

20060292115 - Methods and compositions for treating and preventing inflammatory conditions: Methods of treating eosinophilia by down regulating eotaxin and at least one other Th-2 related cytokine are dislosed as are multivalent immunogenic compositions that generate an active immune response in a subjet comprising autoantibodies to eotaxin-1, eotaxin-2, IL-4, IL-5, IL-9, and IL-13 and treatment methods using such compositions.... Agent: Hoxie & Tso LLP

20060292123 - Adeno-associated virus-mediated delivery of gdnf to skeletal muscles: Compositions and methods for delivering GDNF to skeletal muscles to result in a therapeutic effect are disclosed. The compositions and methods use adeno-associated virus (AAV)-based gene delivery systems. The methods are useful for treating motoneuron diseases, such as amyotrophic lateral sclerosis (ALS).... Agent: Robins & Pasternak

20060292122 - Adenoviral vectors for treating diseases: Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous... Agent: Onyx Pharmaceuiticals, Inc.

20060292120 - Compositions and methods for sirna inhibition of angiogenesis: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types... Agent: Pepper Hamilton LLP One Mellon Center

20060292118 - Hollow nanoparticles of protein and drug using the same: The subject invention is hollow nanoparticles that comprise particle-forming first proteins (e.g. hepatitis B virus surface-antigen protein), containing a bio-recognizing molecule for recognizing a specific cell, wherein at least one of the first proteins interacts with a second protein (e.g. hepatitis B virus core-antigen protein) forming a capsid structure. With... Agent: Nixon & Vanderhye, PC

20060292117 - Improved raav vectors: Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions that specifically target mammalian cells, such as pancreatic islets cells, that express low-density lipoprotein receptors on their cell surface.... Agent: Haynes And Boone, LLP

20060292119 - Modulation of negative immune regulators and applications for immunotherapy: The invention includes compositions and methods for enhancing immunopotency of an immune cell by way of inhibiting a negative immune regulator in the cell. The present invention provides vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The present invention also provides a mechanism... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20060292121 - Retroviral vectors including modified envelope escort protein: A retroviral vector comprising a first retroviral envelope protein and at least one modified retroviral envelope protein, wherein said first retroviral envelope protein includes a surface protein comprising (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion, and said modified retroviral envelope protein, prior... Agent: Wilson Sonsini Goodrich & Rosati

20060292130 - 2-o sulfatase nucleic acid compositions: The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present... Agent: Wolf Greenfield & Sacks, PC

20060292131 - Chondrocyte therapeutic delivery system: Methods and compositions for producing therapeutic agents using chondrocytes are provided. The genetically engineered chondrocytes can be used to express the therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes.... Agent: Nutter Mcclennen & Fish LLP

20060292132 - Neuroprotective effective compound: The present application discloses a method of preventing degeneration of nerve, which includes: a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily or neurotrophic factor proteins operatively linked to a promoter; b) transfecting in vitro a population of... Agent: Jhk Law

20060292129 - Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof: The present invention relates to a cell line selected from the group consisting of (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606; (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and subclones of (a) or (b). Additionally, the present invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20060292124 - Novel process for commercial production of biopesticides: The invention relates to a process for producing biopesticides based on Trichoderma harzianum, Pochonia chlamydosporia and Pseudomonas fluorescens comprising preparing mass or stock culture of biocontrol fungi and bacteria on sawdust, soil and molasses mixture, and then immobilizing the bioagents in a flyable based carrier.... Agent: The Webb Law Firm, P.C.

20060292133 - Use of lactobacillus salivarius: Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract.... Agent: Jacobson Holman PLLC

20060292127 - Beta cell growth and differentiation: The invention includes methods that can be used to increase β cell populations in vivo and in vitro, useful in the treatment of diabetes and related disorders.... Agent: Fish & Richardson PC

20060292126 - Epidermal and dermal equivalents: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood... Agent: Fulbright & Jaworski L.L.P.

20060292125 - Methods for treating ischemic tissue: Compositions and methods for treating ischemic tissue are provided herein.... Agent: Dechert LLP

20060292128 - Methods of treating schizophrenia: The invention provides methods for the treatment of abnormal psychiatric states, particularly the negative symptoms of schizophrenia and extrapyramidal side effects (EPS) of antipsychotic drugs. The inventive methods relate to the administration of therapeutic cells (which produce dopamine or dopamine precursors) adhered to support matrices to subjects suffering from the... Agent: Morrison & Foerster LLP

20060292134 - Composition for enhancing cellular energy: A composition for enhancing cellular energy that includes creatine, L-arginine-α-ketoglutarate, D-ribose, L-carnitine, L-citrulline, and pyruvate. The composition is administering to a subject to enhance cellular energy, to increase relative intensity of physical activity performed by the subject, to increase endurance of the subject during the physical activity and to increase... Agent: Kramer & Amado, P.C.

20060292135 - Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl: A composition and method for treating bacterial infections by the use of an effective amount of at least one lytic specific for the bacteria causing specific. The lytic enzyme is genetically coded for by a bacteriophage which may be specific for said bacteria. The enzyme may be at least one... Agent: Jonathan E. Grant

20060292136 - Cytotoxic factors for modulating cell death: Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death or uncontrolled growth. The present inventors have found that different microorganisms... Agent: Preston Gates Ellis & Rouvelas Meeds LLP

20060292137 - Cytotoxic ribonuclease variants: This invention relates to cytotoxic variants of human ribonuclease 1 (RNase 1) identified through analysis of the interaction between RNase 1 and the human ribonuclease inhibitor (hRI) as defined by the three dimensional (3-D) atomic structure of the RNase 1 hRI complex. Also disclosed is the 3-D structure of the... Agent: Quarles & Brady LLP

20060292138 - Allergen vaccine proteins for the treatment and prevention of allergic diseases: The present invention provides fusion proteins comprising an allergen sequence linked via an IgG hinge region to another polypeptide sequence capable of specifically binding to a native IgG inhibitory receptor containing an immune receptor tyrosine based inhibitory motif (ITIM). They are designed to cross-link an Fc receptor for IgE (e.g.,... Agent: Seed Intellectual Property Law Group PLLC

20060292139 - Fusion proteins for prodrug activation: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20060292140 - Humanized immunoglobulin reactive with alpha4beta7 integrin: The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20060292144 - Human disintegrin protein: Provided is a new disintegrin polypeptide, methods of making such polypeptides, and methods of using them to treat disintegrin-associated disorders and conditions and to identify agents that modulate Metalloproteinase-Disintegrin polypeptide activities.... Agent: Immunex Corporation Law Department

20060292141 - Inhibition of factor b and the alternative complement pathway for treatment of traumatic brain injury and related conditions: Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those... Agent: Sheridan Ross PC

20060292142 - Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies: The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. “Humanized” anti-CD3 mAbs, such as gOKT3-5 and gOKT3-7, have been shown to retain, in vitro, all the properties of native OKT3, including T cell activation which has been correlated,... Agent: Jones Day

20060292143 - Novel t-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof: Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein... Agent: Cooper & Dunham, LLP

20060292148 - Antihuman tnf-alpha antibody activity lowering inhibitor: The present invention provides an antihuman TNF-α antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-α antibody; and a kit preparation wherein a freeze-dried antihuman TNF-α antibody and the activity lowering inhibitor in the above repeated... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20060292147 - Blood mmp-3 level-lowering agent comprising il-6 antagonist as active ingredient: A blood matrix metalloprotease-3 (MMP-3) level-lowering agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.... Agent: Foley And Lardner LLP Suite 500

20060292145 - Human antihuman interleukin-18 antibody, fragment thereof and method for using same: A human-derived human anti-human IL-18 antibody of the present invention is an antibody against human IL-18, the antibody including: an H-chain complementarity determining region consisting of (a) a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 4 to 6, or (b) a polypeptide which is a mutant of... Agent: Edwards & Angell, LLP

20060292146 - Isolated ptpmt1 protein which mediates insulin production and uses thereof: The invention identifies a novel protein tyrosine phosphatase, PTPMT1. The complete nucleic acid and amino acid sequence encoding PTPMT1 is provided. Methods are provided for preventing and/or treating type II diabetes by regulating PTPMT1 levels, which in turn regulates insulin levels.... Agent: Mandel & Adriano

20060292152 - Antibodies directed against amyloid-beta peptide and methods using same: Antibodies directed to the C-terminal side of β-amyloid peptide and methods of using these antibodies for diagnosing and treatment of Alzheimer's disease and Aβ peptide associated diseases are described.... Agent: Morrison & Foerster LLP

20060292151 - L-sign polymorphisms and methods involving use of same: This invention concerns methods for determining whether an agent preferentially binds to at least one allelic variant of L-SIGN. The invention is also directed to agents that preferentially bind to at least one allelic variant of L-SIGN. The invention also provides methods and agents for treating and preventing disorders associated... Agent: Cooper & Dunham, LLP

20060292150 - Methods of using wisp antagonists: Methods and compositions for use in blocking or inhibiting the activity(s) of WISP-1 polypeptide on chondrocytes are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize the effects of WISP-1 on mammalian chondrocytes.... Agent: Genentech, Inc.

20060292153 - Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders: An isolated polypeptide is provided, comprising an amino acid sequence being at least 88% homologous to SEQ ID NO: 15 as determined by BlastP using default parameters, the isolated polypeptide being capable of promoting cell adhesion and/or cell homing.... Agent: Martin D. Moynihan Prtsi, Inc.

20060292149 - Variable antibodies: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the... Agent: Clark & Elbing LLP

20060292154 - A34 and a33-like 3dna, proteins, antibodies thereto and methods of treatment using same: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a... Agent: Crowell & Moring LLP Intellectual Property Group

20060292155 - Diagnostics and therapeutics for diseases associated with mosaic serine protease (msp): The invention provides a human MSP which is associated with the cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases, urological diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular... Agent: Banner & Witcoff

20060292156 - Genetically modified human natural killer cell lines: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD 16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ,TCR-ζ,... Agent: Dykema Gossett PLLC

20060292157 - Mda-7 protein variants having antiproliferative activity: The invention relates to the mda-7 gene, its encoded protein and fragments of the protein. Several of these fragments of the MDA-7 protein exhibit antiproliferative activity and/or inhibited the activity of intact MDA-7. Accordingly, the invention provides, among other things, for methods and compositions that may be used in the... Agent: Wilmer Cutler Pickering Hale And Dorr LLP Columbia University

20060292158 - Method for the treatment of cancer using a novel pharmaceutical composition containing at least one dolastatin 10 derivative: e

20060292159 - Methods for the inhibition of neovascularization and cancer metastasis: Methods for diagnosing a neoplasia of epithelial tissues are provided. The methods comprise quantifiably detecting T-cadherin expression on tissue samples and comparing the detected T-cadherin levels with reference values for the level of expression of T-cadherin in healthy or disease states. Methods for diagnosing the stage of a neoplasia are... Agent: Woodcock Washburn LLP

20060292160 - Human igm antibody inducing apotosis in hiv-infected cells and remedy for hiv-infection: A monoclonal antibody falling within the category of human IgM which specifically recognizes HIV-infected cells and induces apoptosis is obtained. Using the obtained antibody, it is intended to provide a remedy for patients suffering from HIV-infection, which contains as the active ingredient a human IgM antibody capable of specifically reacting... Agent: Adams Evans P.A.

20060292162 - Plasma or serum fraction for the treatment or prevention of bacterial infections: The present invention relates to a plasma or serum fraction derived from a mammal exposed to an inoculant (e.g., a bacteria-bearing inoculant), which fraction has been depleted of one or more high molecular weight proteins or biological agents present in the unprocessed plasma or serum, as well as to a... Agent: King & Spalding LLP

20060292161 - Protective epitopes of adenyl cyclase-haemolysin (ac-hly), their application to the treatment or to the prevention of bordetella infections: Purified nucleic acids comprising a nucleotide sequence encoding an immunogenic polypeptide of adenyl cyclase-haemolysin (AC-Hly), which induces formation of protective antibodies against an infection by a bacteria selected from the group consisting of B. pertussis, B. parapertussis, and B. bronchiseptica when the nucleic acid or polypeptide is administered to a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20060292163 - Phytol derived immunoadjuvants and their use in vaccine formulations: This invention relates to a novel immunoadjuvant, an adjuvant component, and vaccines containing the adjuvant component. The adjuvant includes phytol or a phytol derivative. The adjuvant component, when combined with a soluble or particulate antigen, provides a vaccine with an enhanced ability to induce both humoral and cytotoxic immune responses... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20060292165 - Compositions and methods for enhancement of major histocompatibility complex class i restricted antigen presentation: Compositions and methods for eliciting an in vivo cytotoxic lymphocyte (CTL) response against a modified soluble protein antigen are disclosed. The modified soluble protein antigen comprises an added peptidic sequence which facilitates entry of the modified antigen into antigen presenting cells (APC).... Agent: Perkins Coie LLP

20060292164 - Method for preventing rejection of transplanted tissue: Methods of preventing rejection of transplanted tissue. Recipient alloactivated regulatory T cells generated ex vivo are introduced into the recipient before transplantation. Donor antigen is introduced into the recipient after transplantation to boost recipient regulatory T cells.... Agent: Richard F. Trecartin Dorsey & Whitney LLP

20060292166 - Vaccine composition comprising flt3-ligand: Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T... Agent: Sughrue Mion, PLLC

20060292167 - Therapeutic peptides and vaccines: Compositions are disclosed that induce broadly HIV theraputic and vaccine inducing antibodies against diverse HIV clades and relate to the ability to identify HIV gp120-derived short peptide sequence immunogens and various therapeutic compositions made from the identified peptides which compose CCR5 binding sites. Also disclosed are methods of selecting peptide... Agent: Kile Goekjian Reed & Mcmanus

20060292169 - Fusion proteins of mycobacterium tuberculosis antigens and their uses: The present invention relates to fusion proteins containing at least two Mycobacterium tuberculosis antigens. In particular, it relates to bi-fusion proteins which contain two individual M. tuberculosis antigens, tri-fusion proteins which contain three M. tuberculosis antigens, tetra-fusion proteins which contain four M. tuberculosis antigens, and penta-fusion proteins which contain five... Agent: Townsend And Townsend And Crew, LLP

20060292168 - Methylated heparin-binding hemagglutinin recombinant mycobacterial antigen, preparation method and immunogenic compositions comprising same: The invention concerns a methylated immunogenic recombinant peptide sequence comprising mycobacterial heparin-binding hemagglutinin. The invention also concerns chemical and enzymatic methods for preparing such a sequence, the sequence being previously produced in a non-methylated recombinant form then methylated by post-translational modification. The invention further concerns recombinant tools, vectors and host... Agent: Birch Stewart Kolasch & Birch

20060292170 - Vaccine composition against malaria: A vaccine composition useful in the prevention or treatment of malaria comprises a plurality of malaria-derived antigens in combination with an adjuvant which is a preferential stimulator of TH1 cell response.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20060292171 - Moderating the effect of endotoxins: The present invention relates to the use of an oral composition comprising yeast extract, in the manufacture of an oral composition to treat the effects of infection by pathogenic bacteria such as Clostridium difficile. Such effects may include the failure of the integrity of the gut epithelial cells and diarrhoea... Agent: Bell, Boyd & Lloyd LLC

20060292172 - Dengue serotype 1 attenuated strain: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 viruse) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition which comprises a VDV1 strain.... Agent: Stites & Harbison PLLC

20060292173 - Multibacterial vaccines and uses thereof: The present invention provides methods for establishing standards for Gram-negative, Gram-positive, and mixed bacterial cultures. The present invention also provides methods for reproducing Gram-negative, Gram-positive, and mixed bacterial cultures. The present invention further provides methods for preparing multibacterial vaccines. Also provided are multibacterial vaccines prepared in accordance with these methods,... Agent: Mccarthy Tetrault LLP

20060292175 - Chimeric alphavirus replicon particles: Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations... Agent: Novartis Vaccines And Diagnostics Inc.

20060292176 - In ovo vaccine against infectious bursal disease: The present invention relates to a non pathogenic vaccine comprising a recombinant Infectious Bursal Disease virus that includes a recombinant Segment A, designated as rD78GLSNSΔ, that includes sequences from D78 and GLS strains and wherein the NS protein is not expressed.... Agent: Intellectual Property / Technology Law

20060292177 - Postweaning multisystemic wasting syndrome and porcine circovirus from pigs: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in... Agent: Frommer Lawrence & Haug

20060292174 - Self-assembling nanoparticle drug delivery system: A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting... Agent: Preston Gates & Ellis LLP

20060292178 - Proteins encoded by the severe acute respiratory syndrome (sars) coronavirus and a role in apoptosis: Compositions related to expressed severe acute respiratory syndrome (SARS) coronavirus group-specific polypeptides are provided. Further provided are methods and compositions related to the use of these polypeptides, in particular use for inducing apoptosis in cells, diagnosing SARS infection and screening for modulator and inhibitor compounds of such polypeptides and in... Agent: Alston & Bird LLP

20060292179 - Vaccines for immunization against helicobacter: The invention relates to the immunisation of pigs against Candidatus Helicobacter suis using antigens of species related to Candidatus Helicobacter suis.... Agent: Clark & Elbing LLP

20060292180 - Pathogenic escherichia coli associated protein: The present invention provides a polypeptide, called EspA, which is secreted by pathogenic E. coli, such as the enteropathogenic (SPEC) and enterohemorrhagic (EHEC) E. coli. The invention also provides isolated nucleic acid sequences encoding EspA polypeptide, EspA peptides, a recombinant method for producing recombinant EspA, antibodies which bind to EspA,... Agent: Woodcock Washburn LLP

20060292181 - Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof: A method of inducing either a TH1 polarised immune response, a TH2 polarised immune response or a combined TH1 and TH2 response to an antigen and associated vaccine formulations are disclosed. A method is provided for inducing a polarised TH1 response by parenteral administration of microparticles sized such that at... Agent: Synnestvedt & Lechner, LLP

20060292182 - Photoadjuvant immunotherapy: A photoadjuvant immunotherapeutical method includes the steps of providing a phototherapeutical apparatus, comprising a light source, an optical guidance system, and a patient interface; determining a minimal erythema dose; performing phototherapy by irradiating a target surface with the phototherapeutical apparatus; and performing immunotherapy by exposing the irradiated target surface to... Agent: Gergely T. Zimanyi Sidley Austin Brown & Wood LLP

20060292190 - Amelioration of vitrectomy-induced cataracts: Methods to prevent, inhibit, or slow the development of vitrectomy-induced cataracts are disclosed. The methods comprise administering to the eye of a subject a composition comprising an ophthalmologically acceptable carrier or diluent and at least one hydroxylamine compound in a therapeutically sufficient amount to prevent, inhibit, or slow the development... Agent: Woodcock Washburn LLP

20060292184 - Bioadhesive liquid composition which is substantially free of water: A liquid composition for adherence to a bodily surface, notably to a bodily surface, especially a mucosal surface, comprises water-swellable polymer particles suspended in a water-miscible liquid diluent, wherein the liquid diluent is substantially free of water or includes an amount of water insufficient to fully swell the polymer particles.... Agent: Fish & Richardson PC

20060292183 - Microemulsions as precursors to solid nanoparticles: The preparation of novel microemulsions to be used as precursors for solid nanoparticles is described. The microemulsion precursors consist of either alcohol-in-fluorocarbon microemulsions, liquid hydrocarbon-in-fluorocarbon microemulsions, or liquid hydrocarbon-in-water microemulsions. The formed solid nanoparticles have diameters below 200 nanometers and can be made to entrap various materials including drugs, magnets,... Agent: Fulbright & Jaworski L.L.P.

20060292187 - Nerve construct containing living stretch-grown nervous tissue: The present invention relates to mechanically elongated neurons and provides useful compositions, devices and methods for treating a nerve lesion using such mechanically elongated neurons.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20060292188 - Ophthalmic solution with a flavoring agent: The invention provides an ophthalmic solution with at least one flavoring agent to mask flavors in the solution or add flavor to the solution. The flavoring agent can be a sweet flavoring agent (sweetener), or combinations of a sweetener with a sour flavoring agent or a bitter flavoring agent or... Agent: Bausch & Lomb Incorporated

20060292189 - Ophthalmic solution with a flavoring agent as a dosing indicator and method for indicating dosage of an ophthalmic solution: The invention provides an ophthalmic solution with a flavoring agent as a dosing indicator and a method for indicating dosage of an ophthalmic solution. To indicate dosage, a flavoring agent is added to an ophthalmic solution in an amount correlated to the dosage of the ophthalmic solution to be used.... Agent: Bausch & Lomb Incorporated

20060292186 - Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs: A pharmaceutical composition in a form of an anhydrous self-nanoemulsifying oily formulation comprising: one or more therapeutic agent(s) which have low solubility in water or are water-insoluble, vitamin E, one co-solvent selected from propylene glycol and ethanol and mixture thereof one surfactant selected from tyloxapol and from mixture of tyloxapol... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20060292185 - Topical skin preparations for treatment of skin aging comprising a testosterone ester: The present invention concerns Topical skin preparations for the use in the prevention of atrophy and aging of the skin, comprising a testosterone ester with an esterifying acid having between six to eleven carbon atoms.... Agent: Nath & Associates

20060292191 - Use of nanodispersions in pharmaceutical end formulations: A nanodispersion comprises (a) a membrane-forming molecule, (b) a coemulsifier and (c) a lipophilic component, in pharmaceutical end formulations, the nanodispersion being obtainable by (α) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and (β) adding the liquid obtained in step (α) to the... Agent: Ciba Specialty Chemicals Corporation Patent Department

20060292193 - Encapsulated cosmetic composition: The present invention relates to encapsulated cosmetic compositions that are topically applied. The compositions contain at least one frangible capsule that has a seamless shell of a thermo-softening material. The shell is solid at about room temperature and melts upon application to the skin. The shell holds a core cosmetic... Agent: The Estee Lauder Cos, Inc

20060292192 - Pharmaceutical and cosmetic formulations: Pharmaceutical and cosmetic formulations comprising hydrophobic highly disperse silicon dioxide with a tamped density of 70-400 g/l.... Agent: Venable LLP

20060292195 - Tooth drops: Tooth cleaning drops with an outer shell defining an inner chamber filled with a tooth cleaning substance. The outer shell may be made of the same material as the tooth cleaning substance. The drops are placed in a user's mouth and punctured to release the tooth cleaning substance held inside... Agent: Michael Ries

20060292194 - Treatment for burns and adipose deposits using thyroid hormone compound in a human: A topical preparation for treating first and second degree burns includes TriAc. The topical preparation preferably includes less than 10 mg of TriAc per 100 ml of pharmaceutical excipient base. In another embodiment, a topical preparation includes TriAc for decreasing cellulite. In this embodiment, the topical preparation is preferably applied... Agent: Brown & Michaels, PC 400 M & T Bank Building

20060292196 - Formulation for obtaining a pharmaceutical composition, method for obtaining and use thereof: Invention relates to the field of medicine and may be used in medicine, veterinary, biology, biotechnological, chemical-pharmaceutical and food industry, as well as for domestic purposes, etc. as a reagent providing antimicrobial, antiviral and fungicidal capability. Objective of the proposed invention is a creation of pharmaceutical composition that is innocuous... Agent: Ladas & Parry

20060292197 - Manufactured articles comprising a pest-combating composition: An article including a pest-combating composition applied to or incorporated in such article, wherein the pest-combating composition includes capsicum and/or a cruciferous agent selected from among mustard and horseradish, as active ingredients of the composition. The active ingredients may be micro-encapsulated or otherwise formulated for application to the manufactured article... Agent: Intellectual Property / Technology Law

20060292199 - Pmma bone cement containing antibiotic/antibiotics: A PMMA bone cement containing an antibiotic/antibiotics is described which is characterized in that, in the powder component, 0.1-5.0% by weight of water soluble, glasstype antibiotic/antibiotics granules with a particle diameter in the region of 50-1000 μm are contained which are built up of glass-type antibiotic/antibiotics primary particles bonded to... Agent: Kurt G. Briscoe Norris, Mclaughlin & Marcus P.A.

20060292198 - Porous beta-tricalcium phosphate granules for regeneration of bone tissue: A porous β-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 μm, preferably 50-125 μm. The porous β-TCP material provides a carrier matrix for bioactive... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20060292200 - Porous beta-tricalcium phosphate and methods for producing the same: Methods are provided for producing porous β-Tricalcium Phosphate (β-TCP). In the subject methods, β-TCP is combined with graphite to produce an intermediate greenware product. The intermediate greenware product is then sintered to produce porous β-TCP. The subject methods and compositions produced thereby find use in a variety of applications.... Agent: Bozicevic, Field & Francis LLP

20060292201 - Methods for the in situ treatment of bone cancer: The present invention relates to methods for in situ treatment of malignant cells from a cancer associated with bone. In one method, the treatment is for a primary cancer and entails positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or... Agent: Morgan, Lewis & Bockius LLP

20060292202 - Drug delivery device: Drug delivery devices include a beta-carboline active agent for treatment of ophthalmic disorders.... Agent: Bausch & Lomb Incorporated

20060292203 - Methods and compositions for the treatment of ocular disorders: The invention provides methods and compositions for the delivery of lipophilic drugs that are useful for the treatment of various ophthalmological diseases, disorders, and pathologies, including the treatment of age-related macular degeneration, diabetic retinopathy, diabetic macular edema, cancer, and glaucoma.... Agent: Dla Piper US LLP

20060292204 - Flavanone compound and uses thereof: e

20060292205 - Substitute for animal protein in cattle feed: A combination one or more species of lactobacillus bacteria and one or more types of fibrolytic enzymes can be used to replace animal protein in cattle feed. The combination results in a better amino acid balance in the digestive tract of cattle resulting in a better utilization of nitrogen. Less... Agent: Donavon Lee Favre

20060292206 - Devices and methods for treatment of vascular aneurysms: The present invention relates to devices and methods for the treatment of diseases in the vasculature, and more specifically, devices and methods for treatment of aneurysms found in blood vessels. In a first embodiment of the present invention, a two part prostheses, where one part is an expandable sponge structure... Agent: Levine Bagade Han LLP

20060292207 - Chitosan based dressing: The present invention is a dressing capable of hydrotaxis and temperature-sensitivity for a wound or for antisepsis, containing layers of acrylic acid, N-isopropyl acrylamide and chitosan by a grafting through an ionizing radiation, a UV radiation, a peracid process and a freeze-drying process.... Agent: Troxell Law Office PLLC

20060292209 - Reactive hydrophilic oligomers: Hydrophilic compositions are described, which are prepared from a first oligomer containing pendent polymerizable groups and pendent hydrophilic groups, crosslinked with a co-reactive second component oligomer possessing photoinitiator groups. The compositions may be used as in preparation of hydrophilic gel coatings or layers for medical devices.... Agent: 3m Innovative Properties Company

20060292208 - Sulfonated styrene polymers for medical articles and barrier web constructs: Sulfonated styrene copolymer compositions and salts thereof, and their use in drug delivery devices, such as wound dressings, as well as their use for controlling chemical agents and for controlling biological organisms are presented.... Agent: Heslin Rothenberg Farley & Mesiti PC

20060292210 - Percutaneous absorption-type pharmaceutical preparation: A stable percutaneous absorption-type pharmaceutical preparation for percutaneous administration of selegiline or selegiline hydrochloride, which does not suffer a decrease in the cohesive force of the adhesive layer therein even in the presence of sweat components due to perspiration during wear and which is free from cohesive failure and resultant... Agent: Sughrue Mion, PLLC

20060292211 - Ultrasound enhancement of drug release across non-ionic surfactant membranes: A method of targeted drug delivery and imaging using nonionic surfactant vesicles (niosomes) in combination with ultrasound. Niosomes have potential applications in targeted drug delivery and imaging because of their ability to encapsulate therapeutic agents and their enhanced uptake by physiological membranes. Ultrasound may be used to mediate delivery non-invasively... Agent: Smith Hopen, Pa

20060292215 - Abscisic acid against cancer: Abscisic acid (ABA) a naturally ocurring plant hormone has been identified in this invention with potent properties to fight cancer. ABA is able to produce a hyperpolarization condition on plasma membrane through a decrease of intracellular Na+ and K+. Such phenomenon is produced in cancer cells by mediation of ion... Agent: Gonzalo Romero M

20060292213 - Enoximone formulations and their use in the treatment of pde-iii mediated diseases: The present invention provides pharmaceutical formulations of the drug enoximone for use in treatment of disease states in which inhibition of PDE-III may be beneficial.... Agent: Fulbright & Jaworski L.L.P.

20060292214 - Nanoparticulate acetaminophen formulations: The invention is directed to compositions comprising a nanoparticulate acetaminophen composition, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate acetaminophen particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of aches and pain, and... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20060292212 - Use of thickening agents for producing soft capsules and film production method: The invention concerns the gelatinization of viscous aqueous or hydroalcoholic liquid components, buffered or not, intended for the production of films for the manufacture of soft capsules. These compositions are notable in particular in that gelatinization thereof is obtained extemporaneously starting with thickening agents that exhibit the unique property of... Agent: Paul And Paul

20060292216 - Enteric delivery of (-)-hydroxycitric acid: The present invention provides stable encapsulated (−)-hydroxycitric acid (“HCA”) dosage unit forms, uses thereof, as well as and methods of making the same. In particular, HCA and the salts, esters and amides of HCA according to the invention are delivered via enteric vehicles, such as enteric-coated tablets, and also enteric... Agent: Foley & Lardner LLP

20060292217 - Nutritional supplement and soft gelatin capsule delivery system: A nutritional composition and method of introducing the composition into a soft gelatin capsule. The composition includes effective amounts of omega-3 fatty acid, vitamin D and selenium. The method includes forming each component into a unitary form, forming a soft gelatin capsule and introducing the unitary composition into the capsule.... Agent: Blakely Sokoloff Taylor & Zafman

20060292218 - Agent having a destructive effect on malignant tumors and method for the production thereof: Disclosed is an agent which has a destructive effect on malignant tumors and contains alpha-ketoglutaric acid, N-acetyl-seleno-L-methionine, N-acetyl-L-methionine, and a compound that is capable of forming azomethine and is selected among the group 5-hydroxymethylfurfural, dehydroascorbic acid, maltol, and vanillin as an active substance, 5-hydroxymethylfurfural being preferred. The inventive agent can... Agent: The Firm Of Karl F Ross

20060292220 - Compositions and methods for nutrition supplementation: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in... Agent: Preston Gates Ellis & Rouvelas Meeds LLP

20060292219 - Sublingual buccal effervescent: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional... Agent: Cima Lerner, David Et Al

20060292222 - Drug delivery device having zero or near zero-order release kinetics: The present invention is directed to an improved sustained release drug delivery device comprising a drug core, a cup, and a prefabricated crystalline or semi-crystalline polymeric permeable plug.... Agent: Bausch & Lomb Incorporated

20060292221 - Timed-release compression-coated solid composition for oral administration: The present invention was completed based on these discoveries and relates to in a hydrogel-forming compression-coated solid pharmaceutical preparation comprising a core tablet containing drug and outer layer made from hydrogel-forming polymer substance and hydrophilic base, the improvement, a timed-release compression-coated solid composition for oral administration, said composition comprising (1)... Agent: Townsend And Townsend And Crew, LLP

20060292223 - Gel compositions for topical administration: Pharmaceutical gel compositions containing pharmacologically active agent for topical administration, as well as a method of making the same, are disclosed.... Agent: Fitzpatrick Cella Harper & Scinto

20060292224 - Pharmaceutical composition: This invention relates to pharmaceutical formulations comprising particles with a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule. The invention also relates to methods of forming particles comprising a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive... Agent: Alston & Bird LLP

20060292225 - Water soluble analgesic formulations and methods for production: A water soluble analgesic composition includes a plurality of granules. Each of the granules includes a substrate core and a coating disposed on the substrate core forming an agglomerated product, the coating including a salt of an analgesic, but substantially no particles of a non-salt form of the analgesic. The... Agent: Notaro And Michalos

20060292226 - Fatty emulsion injection of seal oil, method for preparation and the use in manufacturing intravenous injection: The present invention relates to a seal oil based lipid emulsion injection, and the main ingredients of which contains 190-210 g/l of refined OMEGA3 seal oil, 11-13 g/l of refined lecithin, 24-26 g/l of glycerol for injection, and balance amount of water. The preparation of the seal oil based lipid... Agent: Wallenstein & Wagner, Ltd.

20060292227 - Extracellular matrix material particles and methods of preparation: A method for preparing a powdered extracellular matrix material is described. A particulate extracellular matrix material wherein at least 90% of the particles detectable by laser diffraction are about 420 microns or less. A particulate extracellular matrix material is also provided wherein at least 50% of the particles detectable by... Agent: Barnes & Thornburg LLP

20060292228 - Composition and therapeutic uses thereof: A physiologically ingestible composition with microstructured water having a density greater than that of double distilled water is used. The composition may further include microstructured water having a cluster factor of at least 10, and may have dissolved oxygen. The physiologically ingestible composition may be administered to heal a wound... Agent: Fleshner & Kim, LLP

20060292229 - Composition and therapeutic uses thereof: A physiologically ingestible composition with microstructured water having a negative oxidation reduction potential of at least −40, and uses thereof are provided. The composition may further included dissolved oxygen that may be present in an amount of 20 ppm to 150 ppm. The physiologically ingestible composition may be administered to... Agent: Fleshner & Kim, LLP

20060292230 - Composition and therapeutic uses thereof: A physiologically ingestible composition with microstructured water having a negative oxidation reduction potential of at least −40, and uses thereof are provided. The composition may further included dissolved oxygen that may be present in an amount of 20 ppm to 150 ppm. The physiologically ingestible composition may be administered to... Agent: Fleshner & Kim, LLP

20060292231 - Composition and therapeutic uses thereof: A physiologically ingestible with microstructured water having an increased pH compared to unstructured water is used. The composition may further include dissolved oxygen that may be present in an amount of 20 ppm to 150 ppm. The physiologically ingestible composition may be administered to address pulmonary deficiencies of a mammal.... Agent: Fleshner & Kim, LLP

20060292232 - Composition and therapeutic uses thereof: A physiologically ingestible composition comprising microstructured water consisting essentially of hydrogen and oxygen atoms and having a melting point lower than double distilled water is used. The physiologically ingestible composition may be administered to treat infection in a mammal.... Agent: Fleshner & Kim, LLP

20060292233 - Composition and therapeutic uses thereof: A physiologically ingestible composition with microstructured water having a density greater than that of double distilled water is used. The composition may further include microstructured water having a cluster factor of at least 10, and may have dissolved oxygen. The physiologically ingestible composition may be administered to treat infection in... Agent: Fleshner & Kim, LLP

20060292234 - Composition and therapeutic uses thereof: A physiologically ingestible with microstructured water having an increased pH compared to unstructured water is used. The composition may further include dissolved oxygen that may be present in an amount of 20 ppm to 150 ppm. The physiologically ingestible composition may be administered to heal a wound or increase a... Agent: Fleshner & Kim, LLP

20060292235 - Composition and therapeutic uses thereof: A physiologically ingestible composition with microstructured water with an ultraviolet spectrophotometric pattern is used. The composition may further include dissolved oxygen that may be present in an amount of 20 ppm to 150 ppm. The physiologically ingestible composition may be administered to treat infection in a mammal.... Agent: Fleshner & Kim, LLP

20060292238 - Composition and therapeutic uses thereof: A physiologically ingestible with microstructured water having an increased pH compared to unstructured water is used. The composition may further include dissolved oxygen that may be present in an amount of 20 ppm to 150 ppm. The physiologically ingestible composition may be administered to treat infection in a mammal.... Agent: Fleshner & Kim, LLP

20060292239 - Composition and therapeutic uses thereof: A physiologically ingestible composition with microstructured water having a negative oxidation reduction potential of at least −40, and uses thereof are provided. The composition may further included dissolved oxygen that may be present in an amount of 20 ppm to 150 ppm. The physiologically ingestible composition may be administered to... Agent: Fleshner & Kim, LLP

20060292240 - Composition and therapeutic uses thereof: A physiologically ingestible composition with microstructured water essentially of hydrogen and oxygen atoms, and dissolved oxygen is used. The composition may further include dissolved oxygen that may be present in an amount of 20 ppm to 150 ppm. The composition may further include microstructured water having a pH of at... Agent: Fleshner & Kim, LLP

20060292236 - Processed water and therapeutic uses thereof: A physiologically ingestible composition of matter obtained by using tuned super-oxygenated and structured water having multiple attributes, and uses thereof are provided. The tuned super-oxygenated and structured water is produced by receiving oxygen enriched water into a coil system and passing the water therethrough, combining water output by the coil... Agent: Fleshner & Kim, LLP

20060292237 - Processed water and therapeutic uses thereof: A physiologically ingestible composition of matter obtained by water preconditioned for electrolysis and the uses thereof are provided. The matter is obtained by using water obtained by adding ozone to the water, and passing the water through a magnetic flux. The processing of water may further include filtering water received... Agent: Fleshner & Kim, LLP

20060292241 - Processed water and therapeutic uses thereof: A physiologically ingestible composition of matter obtained by using super-oxygenated and structured water, and uses thereof are provided. The super-oxygenated and structured water is produced by receiving water from a source, preconditioning the water for electrolysis, performing electrolysis on the preconditioned water to produce alkaline water, combining the alkaline water... Agent: Fleshner & Kim, LLP

20060292242 - Use of zeolithes for reducing the proportion of lactates and ammonium in human and animal organisms: The invention relates to lowering the lactate values or the ammonium values in the blood of mammals, including humans. According to the invention, ground zeolites are administered orally in the form of a consumption product or a drug. In particular, the zeolite is chosen from the group of natural zeolites... Agent: John P White Cooper & Dunham

20060292243 - Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases: A method of treatments for arsenic-sensitive blast-cell related diseases comprising administering a therapeutically effective amount of arsenic compounds to a human or an animal.... Agent: Hershkovitz & Associates

20060292244 - Use of pvp-iodine liposomes for treatment of acne: The invention concerns a method for the production of a pharmaceutical preparation for the treatment of acne forms that is characterized in, that the preparation comprises at least one antiseptic compound associated with a particular carrier.... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20060292245 - Pain relief compositions: A pain relieving composition for topical application is provided that includes magnesium sulfate (Epsom salts). The composition provides magnesium sulfate in an amount effective for providing pain relief. The composition has a viscosity effective for allowing topical application of the composition to an afflicted area where the magnesium sulfate is... Agent: Fitch Even Tabin And Flannery

20060292246 - Characteristic mass spectral fingerprint setting method and rapid identification method for chinese herbal medicines and prescriptions: A characteristic mass spectral fingerprint setting method and a rapid identification method for Chinese herbal medicines or prescriptions are provided, which comprise directly injecting extracts of Chinese herbal medicines or prescriptions into a mass spectrometer with an electrospray ionization interface via an autosampler of a liquid chromatograph without going through... Agent: Ladas & Parry

20060292247 - Neutralizing agent for toxin of clostridium microorganisms: As a safe and easy-to-use neutralizing agent for toxins of Clostridium microorganisms, a neutralizing agent comprising Thearubigin as its effective component is provided.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20060292248 - Biological attack protection kit and method: A portable kit includes one or more different forms of bio-attack protection agents that are effective in killing or disabling harmful biological substances. The kit is easy to transport and is practical for normal, every day use. It contains one or more vessels holding bio-attack protection agents thereby providing personal... Agent: Connors Associates

20060292249 - Oral compositions for the treatment of cellulite: The present invention relates to oral pharmaceutical and cosmetic compositions for the treatment of cellulite containing Vitis vinifera extracts, Centella asiatica triterpenes and dimeric Ginkgo biloba flavonoids, in the free form or complexed with phospholipids.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20060292250 - Supplement composition and method of use for enhancement of anti-inflammation process: A supplement composition for enhancement of anti-inflammation process is provided, which contains nettle leaf extract, hops extract, and turmeric rhizome extract. The supplement composition further includes hyaluronic acid, sodium salt, glucosamine sulfate, and chondroitin sulfate. Further provided is a method of using the supplement composition for enhancement of anti-inflammation process.... Agent: Melvin K. Silverman

20060292253 - Active substance combination of licochalcone a and phenoxyethanol: A cosmetic or pharmaceutical preparation comprising licochalcone A and phenoxyethanol. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.... Agent: Greenblum & Bernstein, P.L.C

20060292251 - Method for enhancing nutrient absorption with astragalosides: There is provided a method for enhancing the absorption of a nutrient in a subject, including administering to the subject an effective amount of a astragaloside compound purified from Astragalus membranaceus var. mongholicus for facilitating transportation of the nutrient across gut cells of the subject.... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20060292252 - Synergistic composition for the treatment of diabetes mellitus: The present invention relates to a synergistic composition for the treatment of diabetes in a subject in need thereof, said composition-comprising Trigonelline of concentration ranging between 20 to 30%, amino acids of concentration ranging between 20 to 60%, and soluble fiber of concentration ranging between 10 to 60%, optionally along... Agent: Merchant & Gould PC

20060292254 - Orally and nasally administered appetite suppressant: Methods are described for suppressing appetite through the nasal and oral administration of a vanillylamide, thereby desensitizing gustatory or olfactory nerves and reducing the appeal of food. Long term desensitization is particularly contemplated.... Agent: Knobbe Martens Olson & Bear LLP

20060292255 - Pharmaceutical and therapeutic compositions derived from garcinia mangostana l plant: The present invention relates to pharmaceutical, therapeutic, nutritional, cosmetic, and dermatological compositions derived from the preicarp (rind) of the Garcinia mangostana L plant and the novel extraction processes used to produce those compositions. Specifically, the present invention relates, in part, to an approximately 0.01% to about 80% mixture of a... Agent: Greenberg Traurig, LLP

20060286030 - Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumor cells: The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumor cells, especially metastatic cutaneous and uveal melanoma cells.... Agent: Lahive & Cockfield

20060286031 - Modulators of tissue regeneration: Proteins which are upregulated in injured or regenerating tissues, as well as the DNA encoding these proteins, are disclosed, as well as therapeutic compositions and methods of treatment encompassing these compounds.... Agent: Fish & Richardson PC

20060286032 - A radiosotope-chitosan complex for treatment of prostate cancer: Disclosed is a composition for treating prostate cancer. The composition for treating prostate cancer comprises as an effective ingredient a radioisotope-chitosan complex that includes a therapeutic radioisotope emitting beta radiation and chitosan. Also, the present invention discloses a kit for preparing the composition. When directly administered to a prostate cancer... Agent: Lucas & Mercanti, LLP

20060286033 - Targeting pulmonary epithelium using adrp: This invention provides novel compositions and me